The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Long-term benefits of the DCF regimen in the JCOG1109 trial for esophageal cancer
Ken Kato, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, discusses the long-term benefits of the docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in the JCOG1109 trial (NCT02188699) for locally advanced esophageal squamous cell carcinoma (ESCC). Results show higher deaths from other diseases in the chemoradiotherapy group, suggesting older patients may avoid pre-surgery radiotherapy. This interview took place during the 2024 ASCO Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role – Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers’ Bureau – Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding – AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
